Stocktoria
China SXT Pharmaceuticals, Inc. SXTC
China SXT Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2018 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $1.9M | $2.0M | $2.6M | $4.8M | $5.2M | $7.0M | $7.0M |
| Gross profit | $248,702 | $367,427 | $553,971 | $426,271 | $1.3M | $2.8M | $2.7M | $4.6M | $3.4M |
| R&D expense | — | — | $184,194 | $200,717 | $367,005 | — | — | — | — |
| Operating income | -$7.1M | -$2.7M | -$2.5M | -$5.6M | -$5.2M | -$2.2M | -$1.3M | $1.8M | $1.6M |
| Interest expense | — | — | — | $476,776 | $36,695 | $1.6M | $3.3M | $5,174 | $779 |
| Income tax | — | — | — | — | $328,146 | -$192,683 | -$101,722 | $252,232 | $440,103 |
| Net income | -$6.2M | -$3.3M | -$3.1M | -$5.9M | -$5.7M | -$2.7M | -$10.3M | $1.5M | $1.2M |
| EPS (diluted) | $-9.13 | $-348.17 | $-4285.66 | $-177.84 | $-137.92 | $-3.82 | — | $0.08 | $0.06 |
| Operating cash flow | -$4.0M | -$2.3M | -$1.9M | -$80,757 | $268,293 | -$1.3M | $934,247 | $239,192 | $1.9M |
| Free cash flow | — | -$2.3M | -$1.9M | — | — | — | $803,408 | -$296,633 | $1.5M |
| Cash & equivalents | $28.2M | $18.1M | $12.1M | $17.4M | — | $13.4M | $7.3M | $9.3M | $657,767 |
| Inventory | $777,059 | $828,053 | $794,855 | $531,254 | $1.0M | $859,696 | $892,767 | $1.0M | $1.3M |
| Total assets | $34.8M | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M | $21.7M | $17.5M | $7.7M |
| Total liabilities | $5.0M | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M | $12.3M | $6.4M | $4.4M |
| Shareholders' equity | $29.7M | $15.4M | $13.9M | $14.7M | $16.1M | $16.0M | $9.4M | $11.1M | $3.3M |
Growth · year-over-year · Revenue CAGR -20.3%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -34.6% | -9.7% | -2.2% | -24.2% | -45.5% | -7.5% | -26.4% | -0.1% | — |
| Net income growth | — | — | — | — | — | — | -768.4% | +29.6% | — |
| EPS growth | — | — | — | — | — | — | — | +27.1% | — |
| Free cash flow growth | — | — | — | — | — | — | — | -120.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-03-31. Facts plus Stocktoria's own computed scores — not investment advice.